ESSA Pharma Ends Phase 2 Trial for Prostate Cancer Drug Following Lack of Efficacy; Stock Drops 70%
    ESSA Pharma Ends Phase 2 Trial for Prostate Cancer Drug Following Lack of Efficacy; Stock Drops 70%
    PRISM Biotech

    November 01, 2024  - by Alex Corbit

    ESSA Pharma Ends Phase 2 Trial for Prostate Cancer Drug Following Lack of Efficacy; Stock Drops 70%

    01 November 2024

    New York, November 01, 2024 - PRISM MarketView - ESSA Pharma (NASDAQ: EPIX) announced the termination of its Phase 2 trial evaluating masofaniten in combination with enzalutamide for patients with metastatic castration-resistant prostate cancer (mCRPC) who had not previously received second-generation antiandrogens. Following an interim analysis that showed no added benefit of masofaniten with enzalutamide over enzalutamide alone, ESSA’s stock dropped 70% premarket.

    ESSA Pharma Inc. - Prism MarketView

    ESSA is a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer. ESSA’s lead clinical candidate, EP

    Read More

    The analysis revealed that enzalutamide alone produced a higher-than-expected PSA90 response rate, a key marker of treatment efficacy. Given that the combination was unlikely to meet the study’s primary endpoint, ESSA concluded that masofaniten would not deliver the anticipated clinical impact. Although the combination was generally well-tolerated, ESSA decided to end all studies involving masofaniten, both as a standalone and in combination therapies, to focus on strategic alternatives.
    In light of this decision, ESSA’s board and management are now exploring strategic options, prioritizing efficient use of resources and capital to deliver the best value to shareholders. The company’s liquidity remains stable, with $126.8 million in available cash reserves as of September 2024 and no long-term debt.
    About PRISM MarketView:
    Established in 2020, PRISM MarketView is dedicated to the monitoring and analysis of small cap stocks in burgeoning sectors. We deliver up-to-the-minute financial market news, provide comprehensive investor tools and foster a dynamic investor community. Central to our offerings are proprietary indexes that observe emerging sectors, including biotech, clean energy, next-generation tech, medical devices and beyond. Visit us at prismmarketview.com and follow us on X.
    To see this content properly accept cookies.
    Disclaimer:
    PRISM MarketView is not a registered or licensed broker-dealer or investment adviser and does not offer investment advice. The information provided in this communication is not intended to constitute an offer to sell, a solicitation of an offer to buy, or a recommendation for any security.
    Contact:
    PRISM MarketView
    info@prismmarketview.com
    646-863-6341
    To see this content properly accept cookies.
    Prism MarketView | Stock Market News & Investment Opportunities
    To see this content properly accept cookies.
    We use cookies to run our website, analyze your use of our services, manage your online preference & personalize ad content. By accepting our cookies, you’ll get relevant content and social media features, personalized ads, and an enhanced browsing experience. To manage your choices, click „Cookie Settings”. Necessary cookies are required for the core website functionality and cannot be rejected. For more information, see our Cookie Policy.
    Cookie settings
    Cookies used on the site are categorized and below you can read about each category and allow or deny some or all of them, except for Necessary Cookies which are required to provide core website functionality. When categories that have been previously allowed are disabled, all cookies assigned to that category will be removed from your browser. You can see a list of cookies assigned to each category and detailed information on those cookies in the “Cookie Policy” tab.
    Necessary cookies
    Some cookies are required to provide core functionality. The website won't function properly without these cookies and they are enabled by default and cannot be disabled.
    Preferences
    Preference cookies enables the website to remember information to customize how the website looks or behaves for each user. This may include storing selected currency region, language or color theme.
    Analytical cookies
    Analytical cookies help us improve our website by collecting and reporting information on its usage.
    Marketing cookies
    Marketing cookies are used to track visitors across websites to allow publishers to display relevant and engaging advertisements. By enabling marketing cookies, you grant permission for personalized advertising across various platforms.